An Act relative to patient access to biomarker testing to provide appropriate therapy
Take action
Record your position on this measure.
Create an account to take a stance, submit a written position, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Overview
This bill aims to improve patient access to biomarker testing for cancer treatment. Biomarker testing identifies specific characteristics in a patient’s cancer that can help doctors determine the most effective treatment options. The legislation seeks to ensure that patients have timely access to these tests, potentially leading to more personalized and targeted therapies. It intends to facilitate appropriate treatment decisions based on individual patient needs.
Key provisions
- Expands access to biomarker testing for cancer patients.
- Aims to reduce delays in obtaining biomarker results.
- Supports the use of biomarker testing to guide treatment decisions.
- Encourages collaboration between healthcare providers and laboratories.
- Focuses on improving patient outcomes through personalized medicine.
Who is affected
- Cancer patients
- Healthcare providers
- Cancer researchers
- Laboratories performing biomarker testing
- Pharmaceutical companies
Notable changes
- The bill seeks to streamline the process of obtaining biomarker testing.
- It focuses on improving access rather than mandating specific testing procedures.
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
62 on record
Primary sponsor
Meghan K. Kilcoyne
Cosponsors
Adrianne Pusateri Ramos
Amy Mah Sangiolo
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours